1-833-256-2748
M
-
F
,
8
am -
6
pm ET
Call an Alnylam Assist® Case Manager Icon

Frequently Asked Questions (FAQs)

What is Alnylam Assist™?

Alnylam Assist™ includes Case Managers, Patient Education Liaisons, and Field Reimbursement Directors who provide support to patients prescribed Alnylam therapies. This support includes: verification of insurance benefits, coverage and reimbursement education, financial assistance support for eligible patients, and disease and product education. Each member of our team is assigned to specific geographic regions to work with patients, their caregivers, healthcare providers, and insurance companies to support patients throughout treatment on ONPATTRO® (patisiran).

How do I enroll my patients in the Alnylam Assist™ program?

There are 3 ways to enroll your patients:

  1. Complete the electronic Start Form

    •You will receive an auto-generated confirmation after submission to let you know we have received the Start Form and are initiating support services

    •You and your patient will each receive a phone call from their Alnylam Case Manager within 2 business days of receipt

  2. Download the writable PDF version—which can be completed in English, Español, Português Europeau, and Português Brasileiro—and fax the completed Start Form to Alnylam Assist™ at 833-256-2747

    •You and your patient will receive a phone call from an Alnylam Case Manager within 2 business days of receipt

  3. Begin filling out the DocuSign form and DocuSign will send the form to your patient to complete

    •Once you have finished your portion of the Start Form and provided an eSignature, it will be emailed to your patient so they can verify the information and fill out any remaining fields

    •Both you and your patient will receive notification via email when the completed Start Form has been submitted to Alnylam Assist™

    •An Alnylam Case Manager will reach out to you and your patient within 2 business days of receiving the completed Start Form

    •For help submitting the DocuSign form, download our DocuSign Instructions.
    See how to enroll your patients ›

Where can I find more materials about ONPATTRO and Alnylam Assist™?

Support and educational materials about ONPATTRO and Alnylam Assist™ can be found on this site. See additional materials ›

What support services does Alnylam Assist™ Provide?

Alnylam Assist™ provides patients with product support services, including:

•Benefit verification for ONPATTRO

•Education about the prior authorization, claims, and appeals processes

•Financial assistance program enrollment for eligible patients*

•Information about the polyneuropathy of hereditary ATTR (hATTR) amyloidosis and treatment with ONPATTRO

•Ordering Product

Get more information about patient services ›

*Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue any program at any time.

Who makes up the Alnylam Assist™ team?

Case Managers are experienced in helping individuals get started on treatment and providing ongoing support. They will tailor their method of communication based on each individual's personal needs. Here’s how Case Managers provide additional patient support ›

Field Reimbursement Directors (FRDs) provide education about coverage, coding, and reimbursement for ONPATTRO®. FRDs are knowledgeable about ONPATTRO billing and coding requirements. Here’s more information about the FRD role ›

Patient Education Liaisons (PELs) have backgrounds in nursing, and are experienced in educating individuals and their families about matters related to hATTR amyloidosis. PELs can help patients in a variety of ways, including providing disease and product education, connecting patients to additional resources, and answering questions about treatment with ONPATTRO. PELs are employees of Alnylam Pharmaceuticals and do not provide medical advice. Get acquainted with members of the PEL team ›

•The purpose of Alnylam Patient Education Liaisons (PELs) is to provide education to patients, their families, and caregivers

•PELs are employees of Alnylam Pharmaceuticals and do not provide medical advice

•All diagnosis and treatment decisions should be made by the treating physician and their patients

Enrolling Your Patients

Together with your patient
(in office)

Alnylam Assist® electronic Start Form icon

Electronic Start Form

Begin Here ›

or

Alnylam Assist® Start Form - To Print And Fax

Print
& Fax

Download Form ›

Initiate then send to patient
(via email)

Alnylam Assist® Start Form - To Email To Patient

DocuSign eSignature

Begin Here ›

HCP triangle

IMPORTANT SAFETY INFORMATION

Infusion-Related Reactions

Infusion-related reactions (IRRs) have been observed in patients treated with ONPATTRO® (patisiran). In a controlled clinical study, 19% of ONPATTRO-treated patients experienced IRRs, compared to 9% of placebo-treated patients. The most common symptoms of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache.

To reduce the risk of IRRs, patients should receive premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) at least 60 minutes prior to ONPATTRO infusion. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the infusion and instituting medical management as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms have resolved. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed. 

Reduced Serum Vitamin A Levels and Recommended Supplementation

ONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking ONPATTRO. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with ONPATTRO, as serum levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g. night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with ONPATTRO were upper respiratory tract infections (29%) and infusion-related reactions (19%).

INDICATION

ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about ONPATTRO, please see the full Prescribing Information.